InsiderTape plots every Form 4 on the price chart and flags cluster buys, CEO conviction, and first buys in years the moment they file. Start a free 7-day trial, cancel anytime.
START FREE TRIAL →Justin Chakma, Chief Business Officer, is a corporate insider tracked by InsiderTape across 1 company. The public record shows 12 open-market SEC Form 4 transactions: 0 purchases worth $0 and 12 sales worth $8.3M, reported from Nov 25, 24 to Nov 12, 25. Over this period they have been a net seller.
| Date | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 12, 25 | SPRYARS Pharmaceuticals, Inc. | SELL | 136.4K | $8.91 | $1.2M |
| Dec 13, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 27.3K | $12.06 | $329K |
| Dec 12, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 117.3K | $12.27 | $1.4M |
| Dec 10, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 50.0K | $13.15 | $658K |
| Dec 6, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 50.0K | $14.23 | $712K |
| Dec 5, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 49.6K | $14.13 | $701K |
| Dec 4, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 45.0K | $13.95 | $628K |
| Dec 3, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 45.0K | $13.19 | $594K |
| Dec 2, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 45.0K | $13.67 | $615K |
| Nov 27, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 25.0K | $14.39 | $360K |
| Nov 26, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 42.2K | $14.05 | $593K |
| Nov 25, 24 | SPRYARS Pharmaceuticals, Inc. | SELL | 32.8K | $14.00 | $459K |